A JAK Inhibitor Offers a Lifeline for Severe, Steroid-Resistant Liver Injury
A new prospective proof-of-concept study published in Liver International investigates a novel rescue strategy for a life-threatening condition: corticosteroid-refractory drug-induced liver injury (DILI) accompanied by severe DRESS syndrome. The research focuses on the use of tofacitinib, a Janus kinase (JAK) inhibitor, in patients whose severe liver injury, marked by sharply elevated ALT and bilirubin levels, continued to worsen despite standard corticosteroid treatment. The findings demonstrate that oral tofacitinib administration led to a rapid reversal of hepatotoxicity in all four treated cases, with transaminases and bilirubin normalizing and associated cutaneous symptoms resolving completely. This study provides critical early evidence that targeting the JAK-STAT signaling pathway can effectively counteract the cytokine storm believed to drive this severe form of DILI.
Study Significance: For hepatologists managing complex cases of DILI, this research introduces a potentially paradigm-shifting therapeutic option for a subset of patients with high mortality risk. It directly addresses a significant clinical gap where effective second-line therapies are undefined. The successful application of tofacitinib not only offers a concrete treatment strategy but also validates the pathogenic role of specific inflammatory pathways in severe hepatotoxicity, which could guide future drug development and diagnostic approaches for immune-mediated liver injury.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
